Neuronal development, function, and the subsequent degeneration of the brain are still an enigma in both the normal and pathologic states, and there is an urgent need to find better targets for developing therapeutic intervention. Current techniques to deconstruct the architecture of brain and disease-related pathways are best suited for following up on single genes but would take an impractical amount of time for the leads from the current wave of genetic and genomic data. New technical developments have made combined high-throughput-high-content (HT-HC) cellular screens possible, which have the potential to contextualize the information, gathered from a combination of genetic and genomic approaches, into networks and functional biology and can be utilized for the identification of therapeutic targets. Herein we discuss the potential impact of HT-HC cellular screens on medical neuroscience.
Introduction
Although human genome research is still a very young discipline, it already plays a central role in biomedical research aimed at understanding the molecular mechanisms underlying human (disease) phenotypes. Since the discovery in the 1980s that DNA polymorphisms could be used to create genetic linkage maps (Botstein et al., 1980) , they have become an essential tool for gene discovery and are instrumental for the identification of many pathogenic mutations for human diseases. Currently, pathogenic mutations for human disorders in thousands of genes have been identified by linkage and positional cloning approaches, including genes, among many others, for neurodegenerative disorders such as the Amyloid Precursor Protein (APP) and Presenilin (PS1 and PS2) genes for familial forms of Alzheimer disease (AD), or the a-synuclein and Leucine-rich repeat kinase 2 (LRRK2) genes for Parkinson disease (PD) (Bettens et al., 2010; Cookson and Bandmann, 2010) . The subsequent functional characterization of the causative genes has significantly increased our understanding of pathogenic mechanisms of disease and is continuously providing us with new starting points for research toward better therapeutic approaches.
Encouraged by these successes and by the quickly evolving methodologies to study DNA variation on a genome-wide scale, human genome research has shifted from identifying and characterizing single genes for Mendelian disorders toward more complex and multifactorial diseases in which tens to hundreds of genetic and environmental risk factors play a role. This shift of attention is nicely illustrated by the recent wave of genome-wide association studies (GWAS) that has revealed large numbers of often relatively small risk factors for multifactorial neurodegenerative diseases such as AD, PD, and amyothropic lateral sclerosis but also for mental illnesses such as schizophrenia, bipolar disease and autism (Hindorff et al., 2010) . Much of this progress was made possible by the development of high-density arrays for SNP genotyping. Similar to SNP arrays, array-based analyses of gene expression, regulatory sequences, and proteins have been developed and are widely used. The breakneck speed of technological developments in genomics is demonstrated by the recent developments in the field of sequencing. Next-generation or massive parallel sequencing (MPS) of whole-exome DNA is quickly replacing classical linkage studies (Biesecker, 2010; Krawitz et al., 2010; Ng et al., 2010) , and, similarly, new MPS-based sequencing of RNA instead of microarrays has the clear advantages that it can measure expression variation on a genome-wide level and is less biased by the selection of content like microarrays (Metzker, 2010) . MPS can easily be combined with other genome-wide techniques to detect epigenetic changes such as methylation (MeDIP-seq) (Laird, 2010) or DNA-protein interactions like transcription factor binding (ChIP-Seq) (Park, 2009) . Just a few years after the introduction of the first-generation sequencers of this kind, a new generation, some able to sequence single molecules without amplification steps, has already entered the market, making whole-genome sequencing on a large scale feasible (Metzker, 2010) . These technical developments have changed the field of human genetics and have contributed to the successes of the field. As a consequence, a considerable part of the heritability of complex diseases can now be explained although the majority of genetic factors still remains to be identified (Manolio et al., 2009) .
The discussion of how to find these remaining genetic risk factors, often referred to as ''missing heritability,'' is largely based on statistical arguments geared toward increased statistical power to detect a genetic risk factor (Maher, 2008; Manolio et al., 2009) . As a result, increasingly large study samples are being genotyped or used for large-scale targeted resequencing to detect rare genomic variants with small effect sizes. While these measures will undoubtedly help, they will not provide the final solution. To really move forward and fully understand genetic risks and use this knowledge for therapy development, we need to think how we can use biology to help dissect the genetic risk factors for human disorders. For example, genetic association studies generally test for the association of a clinical phenotype with a single genomic variant at a time (usually a single-nucleotide polymorphism, or SNP) and repeat this test for all SNPs tested. This method is very powerful to detect the effect of a single risk factor for a phenotype, and by combining p values from different SNPs one can detect the additive effect of multiple risk factors. However, from biology it is clear that genes do not act by themselves but that they function in gene networks and molecular pathways and that their actions are often not simply additive but often epistatic. The use of single SNP association tests is therefore an oversimplification of the biological situation because these epistatic effects will not be detected. In addition, the biological effect of single genes is exerted on a single pathway, but often they function in several distinct pathways with temporal and tissue-specific regulation. It is therefore important to widen our attention to gene networks. We and others are developing statistical methods to detect joint (both additive and epistatic) effects of genes in genetic data (Bochdanovits et al., 2008; Cordell, 2009; Ruano et al., 2010) .
Although there has been remarkable success in identifying genes for Mendelian disorders and we now seem to be able to identify reproducible (although relatively small) risk factors for complex diseases, the translation of genetic knowledge to effective therapy has, in our opinion, been disappointingly slow. The available treatment options for most neurological and neurodegenerative diseases are not curative, and successful medications like L-DOPA for PD have not been developed based on genetic findings. In this we feel that genetics has not yet fulfilled its promise for faster therapy development, and it is important to realize what the reasons are for this lack of translation.
The identified genetic risk factors for Mendelian diseases are attractive leads for developing treatments because they act at the very start of the pathogenic process; however, the genes themselves are often not the most suitable targets for drug development. Many of the mutated products turn out to be difficult to modulate using chemicals compounds, or they act in multiple pathways complicating the development of effective medication with high efficacy and specificity but importantly also with limited side effects. For example, the LRRK2 gene is an important risk factor for PD. At first glance the gene seems an excellent candidate for developing a chemical compound as the mutations are dominant gain-of-function mutations of its kinase activity. However, even in this case, developing a suitable compound is a daunting task. The gene is widely expressed in brain and other tissues, during both development and adult life, which complicates the development of a compound that affects only its activity in the relevant brain area and that has no off-target effects on other kinases. On the other hand, even if the identified risk factors might not be the most suitable drug targets themselves, they do point to molecular pathways that are at the basis of the pathogenesis of disease. Therefore, treatment strategies targeted at other key gene products in the same affected pathways, which might be easier to target or have a higher specificity, could lead to more successful therapeutic approaches. Consequently, a systematic functional characterization of genes within the context of their molecular pathways is essential for the translation of genetic findings toward therapy.
For multifactorial diseases, an even more complex situation exists. GWAS are not designed to directly identify the relevant biological variant, but, similar to linkage studies, they point to a location of the genome where a risk variant is located. This is because GWAS test only a selection of genome variants, usually in the range of 500,000 to 1 million SNPs under the assumption that they capture the information of all other variants of the genome. This assumption, based on the concept of linkage disequilibrium (LD) or the nonrandom association of alleles at two or more loci (usually physically close), allows to reduce the number of SNPs to be tested because if two SNPs are in high LD, testing one SNP will provide information on the genotype of the other SNP. It is therefore possible to test for all genetic variation without genotyping every SNP in a chromosomal region. A drawback is that, because only a small proportion of genomic variation is actually tested, the chances that the biologically relevant variant is tested are small and that the subsequent identification of the biologically relevant mutation located under the association peak is often problematic because the functional annotation of the human genome is very limited. Unfortunately, the current information in the genome databases is still heavily biased toward protein coding genes that have been extensively studied in classical molecular and cell biological experiments, but we have very little knowledge about the possible function of the remaining 98% of our genome, which consists of noncoding DNA. The ENCODE and FANTOM projects have given us a first glance at how complex our genome really is (Birney et al., 2007; Carninci et al., 2005; Katayama et al., 2005) . Most of our genome is transcribed into (noncoding) RNAs of all sorts and our classical gene models are under discussion. This is a major problem for interpretation of our GWAS findings since in most studies the association is found with SNPs that reside in noncoding regions of genes or in intergenic regions, and it is unclear what their biological functionality could be. The interpretation of the possible biological consequences of identified risk variants therefore requires a much better understanding of the functions of our genome, especially for those located outside the well-annotated protein coding regions. Considering the speed at which GWAS and other ''omics'' data sets are currently being published, it is obvious that obtaining a full functional annotation of our genome cannot rely on detailed cell biological studies on single genes alone. The task would take an impractical amount of time and work using standard molecular and cell biological approaches. Because of the scale of the task and because of the recent technological developments, functional studies of genes are becoming more and more dependent on outcomes of high-throughput (HT) functional genome analyses. By extending the technological advancements for HT analysis with the available multidimensional or high-content (HC) cell biological approaches based on single genes to gene networks and to a genome-wide scale, we can now identify modifying genes and molecular pathways of disease-causing genes as well as dissect components of multifactorial phenotypes at a much faster rate. Use of this combination of HT methods with HC cellular screens can also aid in the development of therapeutic targets and help to understand fundamental biological processes. We shall present an overview of the important aspects of conducting a HT-HC cellular screen and discuss the possible application of this methodology in medical neuroscience.
High-Throughput-High-Content Screening Successful therapy development for neurological disease requires a thorough understanding of the relationship between the variation present in our genome and the corresponding molecular phenotypes in relation to clinical phenotypes. As discussed above, the functional annotation of the human genome is a major bottleneck in this process, but in addition there is a lack of ''connectivity'' with pathways for most of the genes in the genome because we have little knowledge about most genes' functional interactions. This lack of information makes it such that many of the genetic variants we identify as associated with a disease cannot be evaluated for their role in their proper molecular environment. Interactions between genes are often subtle and complex and require a multidisciplinary approach in which genomic information, gene and protein expression levels, and cell biological parameters are integrated. The ability to collect this information rapidly and inexpensively has long been a bottleneck to realizing this goal. However, in recent years genomic approaches have entered a functional evaluation phase, and newly developed HT methods now provide enormous amounts of raw data for that purpose (Fan et al., 2006) .
The first HT screens (HTS) were developed within the pharmaceutical industry and were the mainstay of drug discovery (Hertzberg and Pope, 2000) . In this context, HTS conduct thousands to millions of biological tests to identify compounds, genes, or molecules that are involved in a biological process. Initial assays measured the effect of compounds on purified enzyme activity, on interactions between proteins, or on molecules by using fluorescence, luminescence, or absorbance readouts in simple ''mix and measure'' assays (Inglese et al., 2007a; Macarron, 2006; Macarró n and Hertzberg, 2009 ). These assays have the advantage that any hit identified has a known target, and in combination with advancements in robotics, automation, and assay miniaturization, investigators can screen tens of thousands of different modifiers without bias. This approach has been successful in identifying for example protein kinase inhibitors (Aherne et al., 2002) ; however, many of the compounds or modifiers identified in vitro could not be confirmed in ex or in vivo systems (Houston et al., 2008; Zhang et al., 2000) . As a consequence, alternative methodologies, requiring an intact biological system, have been pursued in which research questions focused more on understanding the interactions between different cellular processes or the function of unknown genes. Since methods to systematically modify gene expression and/or function (e.g., shRNA genome-wide libraries for RNAi-mediated gene silencing, overexpression libraries) are now accessible (Grimm, 2004; Maddox et al., 2008; Moffat et al., 2006) and robotic methods have been developed to allow the automated large-scale cell culturing of mammalian cells, cell-based HTS has become suitable as an investigative tool to interrogate the function of a gene, protein, or pathway using relevant molecular phenotypes within the complex environment of cells, and to bridge the gap between in vitro and whole-animal models (An and Tolliday, 2010; Gasparri, 2010; Kumar et al., 2010; Zhang and Heyse, 2009) .
However, to date, most HT cell-based screens have been whole-well cell assays that quantify one molecular event or use simplistic readouts of complex biological process (e.g., measurement of apoptosis by measuring only caspase 3 activation or measuring cell proliferation by the reduction of the tetrazolium salt MTT)-they have been one-dimensional. While these can be excellent phenotypes to study the effects of compounds or genes on, for example, tumor growth, for neurological diseases they will probably miss subtle but essential effects or changes that are present only in a subset of cells, as is often the case for neurological disorders. To better understand how genes, networks, and environmental factors cooperate to regulate the complex phenotypes in the brain, one has to move from one-dimensional to multidimensional or multiparametric HC phenotypes. HC cellular screens have become feasible after the development of high-quality fluorescent and confocal microscopes including advanced analysis software (for example the Cellomics ArrayScan from Thermo Scientific) and with regard to understanding the complexity of biological processes, has several advantages compared to whole-well HTS (Clemons, 2004; Conrad and Gerlich, 2010; Megason and Fraser, 2007) . The simultaneous quantification of several different processes provides multiple avenues for identifying modifiers of accessible and biologically relevant targets and can thus facilitate identification of gene interactions or improve detection of drug compounds with potentially harmful side effects. In addition, structures or processes that could not be quantified by whole-well HT screens, such as axonal and dendritic growth, can be visualized and quantified with relative ease (Sepp et al., 2008) .
Multiparametric data generated by HCS may also provide information about temporal and spatial changes, thus enabling a more sophisticated understanding of responses in the cell to multiple perturbations. This was elegantly illustrated by a recent study (Miller et al., 2010) using the mutant Huntington protein (HTT). With the use of HCS, authors were able to demonstrate that within a cell, formation of inclusion bodies (IB) was correlated with reduced diffuse (free, nonaggregated) mutant HTT levels and with improved cell viability. The demonstration of this relationship would not have been possible using conventional HTS as one would not have assayed for both IB formation and diffuse HTT levels. In addition, if using a whole-well measure of apoptosis, one would simply observe cell loss and would miss the relationship between IB formation and maintenance of cell viability in a subset of cells.
Unfortunately, HC cellular screens are more expensive and are difficult to establish and conduct on a large scale because of the simultaneous labeling and quantification of several features and the experimental variation one has to deal with when using mammalian cells. However, as technology for automated cell culture, imaging, and algorithms for image analysis is improving, the gap between HCS and HTS is decreasing as many assays have been optimized such that they possess the sensitivity, reproducibility, and economic feasibility for HTS screening (Maddox et al., 2008) .
Experimental Design
To conduct a HT-HC screen and ensure that meaningful data are collected, several aspects have to be considered and optimized. Once a testable hypothesis or biological question has been decided, an assay to monitor the biological process or protein of interest has to be designed. This is one of the most important, time-consuming, and complex aspects of a HT-HC screen, but a high-quality assay for a relevant cellular phenotype is essential for a meaningful screen. An assay is either a biochemical or cellular experiment that provides a qualitative or quantitative measure of a compound, gene, or other molecule (An and Tolliday, 2010; Clemons, 2004; Maddox et al., 2008) .
Assay Design
There are too many cell-based assays to discuss extensively within this review (Figure 1 ), but with the use of chemicals, fluorescent proteins, or genetically encoded biosensors it is possible in principle to quantify virtually any molecular event within the cell (Daub et al., 2009; Dragunow, 2008; Sato et al., 2002 Sato et al., , 2007 Varma et al., 2007) . For example, Sato et al. visualized signal transduction based on protein phosphorylation in living cells by joining two different-color mutants of green fluorescent protein (GFP), YFP, and CFP by a tandem fusion domain composed of a substrate domain for the protein kinase of interest, a flexible linker sequence, and a phosphorylation recognition domain that binds with the phosphorylated substrate domain (Sato et al., 2002) . Intramolecular interaction of the substrate domain and the adjacent phosphorylation recognition domain is then dependent upon phosphorylation of the substrate domain by a protein kinase, which influences the efficiency of fluorescence resonance energy transfer (FRET) between the GFPs. The assay was originally designed to visualize protein phosphorylation by the insulin receptor but can also be adapted for other proteins, for example, the phosphorylation of a-synuclein at Serine 129, which is possibly an early event leading toward a-synuclein aggregation (Chen and Feany, 2005; Gorbatyuk et al., 2008) .
To build reliable assays of this kind not only requires excellent molecular biology skills but is also time consuming and a major bottleneck for performing HT-HC cellular screens. Reliability of the measurement is paramount, and as many of the phenotypes, both natural and diseased, will be the result of large numbers of genes functioning in networks with additive and epistatic interactions, screens should be able to detect such subtle effects. The assay should be able to quantitatively report on the phenotype of interest and be robust with low variability and high signalto-noise ratio. It must have low false-positive and -negative rates, be highly reproducible, and be sensitive (Birmingham et al., 2009; Coma et al., 2009; Malo et al., 2006) . The Z 0 factor is an often used way to estimate assay quality and is calculated as a signal detection window between positive and negative controls scaled by the dynamic range (Zhang et al., 1999) . The ''better'' an assay is, the lower the risk of false positives and negatives. To assess the false-positive and -negative rates, an assay validation should be performed (Macarró n and Hertzberg, 2009). Assay validation consists of a screen containing a representative sample of the screening collection and is conducted in the same way as the actual screen would be performed. Performing the assay validation allows the empirical determination of error rates (Brideau et al., 2003; Zhang and Heyse, 2009 ), spatial effects (Root et al., 2003) , systematic handling errors, and optimal methods for data analysis (Birmingham et al., 2009; Macarró n and Hertzberg, 2009; Makarenkov et al., 2007; Marazìa et al., 2008) . If during the assay validation it is not possible to reliably, robustly, and reproducibly detect the modifiers, it would be necessary to reoptimize the screening procedure and possibly the assay itself (Echeverri and Perrimon, 2006) . Excellent reviews that discuss these issues in more detail are available (Inglese et al., 2007b; Stone et al., 2007) .
Once the assay is built, it is miniaturized to allow the highthroughput administration of thousands of compounds or gene modifiers (for example by RNAi or overexpression) and to minimize cost. During the screen, one has to identify true ''hits'' while minimizing error rates by replication experiments and specific molecular biology approaches (Figure 2 ). The integration of HC-HT data with information generated from other ''omic'' approaches can help to construct a multidimensional or ''systems biology'' overview of the role of ''hits'' within the cell.
Model Systems
An additional layer of complication arises in selecting the appropriate model system in modeling brain diseases. The brain is our most complex organ and consists of different highly specialized cell types that function in a highly integrated way. Single neurons can communicate with tens to many thousands of other neurons, and as many as 10 15 synapses may exist. In contrast to other organs, the main functions of the brain are performed by highly specialized cells that cannot renew themselves by cell division and therefore have to be resistant to a lifetime of insults while performing tasks that require large amounts of energy resulting in a high metabolic rate. For modeling such a complex system, a mammalian animal model comes closest to the desired situation, but using whole organisms limits research to specific questions for obvious logistic reasons. Thus one has to develop representative, standardized ex vivo cell culture models to allow the reliable detection of subtle effects as well as to conduct screens on the scale that it is necessary to deliver targets with the speed and accuracy that is needed. Choosing the best cell type for a particular HC assay is challenging as each option comes with inherent benefits and drawbacks. The decision will largely depend on (1) whether the model is a good representation of the phenotype or mechanism under investigation, (2) the method by which one wants to monitor a cellular phenotype, (3) the method by which one wants to perturb the genes (viral transduction, chemical compounds), and last but not least (4) the scale of the experiments (whole-genome screens versus gene subsets). By necessity, the larger the experiment the easier the model has to be to culture and expand to the numbers that are needed for the experiment. Thus at present for most largescale experiments, such as genome-wide shRNA screens, neuroblastoma cell lines are the primary choice with more complex models such as primary neurons being reserved for smaller screens, confirmation of hits, or detailed molecular follow-up (Boutros and Ahringer, 2008; Daub et al., 2009; Echeverri and Perrimon, 2006; Eglen et al., 2008a Eglen et al., , 2008b ).
Yet, in the living brain, multiple highly specialized cell types function together within blocks of tissue. In contrast, the current ex vivo models, including primary cells, are essentially two-dimensional (2D) and thus do not represent the 3D in vivo situation where different cell types are embroiled in complex cell-to-cell and cell-to-matrix interactions. The architecture and morphology of these structures can have a profound impact on the behavior and gene expression of the cell types involved (Thomas et al., 2002) . Thus methods are being developed to reconstruct the in vivo 3D architecture in an ex vivo environment (Kim, One can modify the cell and determine the pathways controlling the localization of specific RNA transcripts by using fluorescent ribo-probes. Nuclei staining is in blue and RNA staining is in red. (E) Using fluorescently tagged proteins one can monitor the folding and aggregation of specific proteins, which is a common pathogenic mechanism observed in neurodegenerative diseases. The image shows the aggregates of the SNCA protein (green) and nuclei (blue). (F) One can monitor specific posttranslational modifications and determine the pathways that control this modification. If the modification is an important part of the pathogenic processes, one can utilize this information to identify suitable therapeutic targets. The image shows immunostaining for total SNCA (red) and phosphorylated SNCA (yellow). (G and H) Assays conducted in whole organisms can be useful to study processes that are not possible ex vivo or in humans such as nervous system development in (G) Caenorhabditis elegans (staining of all neuronal cells) and (H) Drosophila melanogaster (staining for two RNA species, bHLH and cato, involved in neuronal development) (adapted from zur Lage and Jarman, 2010). (I and J) One can monitor synaptogenesis between pre-and postsynaptic junctions (I) in primary neuronal cocultures and (J) synapse formation on hippocampal DIV12 neurons labeled with synapsin1 (green) and MAP2 (red) (image courtesy of Desiree Schut and Matthijs Verhage). (K) HCS assay for determining modulators of apoptosis (simultaneous staining for nuclei, mitochondria, F-actin, and Beta III tubulin). (L) Labeling of synaptic vesicles using a synthetic construct of NBEA with egfp, duf, ph, and beach domains and MAP2 (blue) (image courtesy of Juliane Lauks and Matthijs Verhage). All the assays can be multiplexed to obtain a multidimensional perspective of either gene function or detect side effects in drug compounds screens. Data from all the different assays in combination with gene modification can subsequently be integrated to obtain a systems biology overview of the cell.
Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 211 Neuron Perspective For this to be truly useful, 3D culturing techniques have to be more standardized, and advances in imaging and image analysis with automated microscopes have to be realized. Microscopes should image through several Z heights and subsequently compile the images to extract the information with the pace that is necessary to facilitate genome-wide screens. At present, automated confocal microscopes (for example, Opera, PerkinElmer) have such capabilities but are limited by their throughput. With the improvements in technology (Megason and Fraser, 2007) and 3D image reconstruction and analysis algorithms, the throughput on such systems is increasing enabling the future usage of 3D cell cultures in HT-HC screening.
Another system with great potential to model neurological phenotypes in cell culture are embryonic stem (ES) cells and induced pluripotent stem (iPS) cells as they combine the advantages of primary cells with those of cell lines. ES and iPS cells have the ability to proliferate and can be subsequently differentiated, in principle, into any neuronal cell type in very large quantities (Salero and Hatten, 2007; Smidt and Burbach, 2007) . This is an extremely exciting approach as this could potentially give rise to an endless supply of human neuronal cells. In addition, these cells might allow us to more realistically model multifactorial diseases than currently possible. For multifactorial disorders, the effect of single gene variants will often be small and subtle and will probably not result in a visible or testable phenotype by itself. Also modeling such a risk factor by simple gene knockout, knockdown, or overexpression might induce severe phenotypes that do not mimic the natural situation. To construct a cellular model that incorporates the realistic effect size of all identified risk factors, likely to be tens to hundreds, is impractical. Therefore, methods to study combinations of risk factors or gene networks are needed. With the discovery that human fibroblasts can be genetically reprogrammed into iPS cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) and redifferentiated into neurons that can retain biochemical and pathological deficits of a given disease (Ebert et al., 2009; Marchetto et al., 2010; Park et al., 2008) as well as form functional neurons in vivo (Wernig et al., 2008) , HT-HCS could use patientspecific cell lines to model multifactorial diseases. Although the potential of ES and iPS cells in HT-HCS is promising, their use is limited at present as protocols to differentiate ES and iPS cells into neuronal cells are costly, requiring large numbers of growth factors; inefficient with great variability in composition of the final culture that is formed; and labor intensive. For ES and iPS to be used in HT-HCS, methods will need to be developed that improve, standardize, and automate their culture and differentiation into consistent and pure populations of specific neuronal types. The neuronal types that can be formed will also need to be characterized in much more detail in terms of expression, epigenetic modifications, and functionality to determine how accurately they represent neurons in vivo.
Outlook
The development of automated high-resolution fluorescent and confocal microscopy and their integration into automated neuronal culturing systems has finally brought cell biology into the domain of other ''omic'' sciences (Cellomics). With the range of assays that can be built and the acquisition of multidimensional phenotypes (Daub et al., 2009; Dragunow, 2008; Thomas, 2010) , the number and the scale of questions that can be asked and answered has increased tremendously. This is not an overstatement, as was shown by a recent genome-wide siRNA screen 
. Workflow for Conducting a HT-HCS Screen
From left to right: the first step of HT-HCS includes the choice of an appropriate library and the development of relevant cellular assays for the scientific question to be answered. This is followed by the production of assay plates with the cultured cells of choice, either transfected with the library of choice or treated with a compound library. The next step consists of HCS imaging for the relevant cellular phenotypes and the data analysis of primary data (i.e., flagging which compounds are giving a positive response in the assay, namely hit identification). Hit identification includes primary and secondary screens to confirm hits. Follow-up experiments for identified hits can be designed. In the case of compound screens, adsorption distribution, metabolism, elimination, and toxicity testing (ADMET) will be done. In the case of functional evaluations or network approaches, more detailed molecular studies, bioinformatic network pathway analysis, data integration, or other experiments can be performed. using approximately 90,000 siRNAs ). The study screened for modifier genes of the circadian clock. Expression of relevant genes follows a rhythmic pattern, and to follow this pattern the authors used a kinetic bioluminescence assay linked to the promoters of the Bmal1 or Per2 genes, which are important genes in regulation of circadian rhythm, as a proxy for their expression. Knockdown of nearly 1,000 genes reduced rhythm amplitude, and several hundreds of genes increased amplitude Characterization of a subset of these genes demonstrated a dosage-dependent effect on oscillator function. Protein interaction network analysis showed that dozens of gene products directly or indirectly associate with known clock components. The study elegantly demonstrated that genomewide screens using complex phenotypes that are relevant in neuroscience have become feasible, even though the study was still performed using manual cell culturing. For screening multiple phenotypes simultaneously and to increase throughput and sensitivity, automated cell culture combined with highcontent imaging could be used. For example, classic genomewide enhancer-suppressor screen for protein aggregation of mutant a-synuclein using a genome-wide shRNA library (TRC1 library, approximately 110,000 clones) (Moffat et al., 2006) , in our own fully automated cell culture and imaging set-up, using cellular phenotypes such as protein aggregation, phosphorylation, protein translocation, neurite outgrowth, mitochondrial integrity, and cell viability simultaneously, can be performed in a few months once suitable assays have been build.
High-throughput techniques for generating and analyzing ''omics'' data have yielded new insights into neurons, such as the discovery of novel genes, regulatory mechanisms, and protein complements (Geschwind and Konopka, 2009 ). However, there is an inherent risk of predicting phenotypic effects from existing ''omics'' data as they require assumptions about gene and protein functions and interactions, prohibiting the identification of novel essential players since most of our genome is not very well functionally annotated and interactions are mostly unknown. Once correlations were identified between integrated data sets (Ge et al., 2003; Walhout et al., 2002) , the effect on different pathways was predicted and experimentally verified on a gene-bygene basis. HT-HC screens now allow the correlation and verification of genome-wide genetic screens, mRNA expression, and quantitative proteomics data, using large-scale cell biology experiments. The concept was elegantly illustrated with two recent studies which combined published mRNA expression profiles with data from a genetic screen in S. cerevisiae to build cellular response networks associated with a-synuclein toxicity Yeger-Lotem et al., 2009) . With the availability of HT-HC screening systems for mammalian cells, not only can these findings now be verified, but screens of a similar size can be directly performed in a mammalian cellular model using phenotypes relevant for neuronal function or neurodegenerative diseases. Furthermore, one is not limited to a simple phenotype as toxicity but could simultaneously measure effects on a-synuclein phosporylation, aggregation, and phenotypes based on morphology such as neurite outgrowth or other phenotypes relevant for disease pathogenesis.
How can these developments be used to translate genetic findings into better therapeutic approaches? Genetic studies such as linkage and genome-wide association studies point toward genes and pathways that are involved in the etiology of disease. After the identification of these factors, researchers face two main questions: how do these mutations or risk factors lead to disease? And how can genetic findings be used for therapy development?
For Mendelian disorders, the classic gene-by-gene experiments have yielded a wealth of data to understand the relevant biological processes. The large majority of mutations identified for Mendelian diseases result in amino acid changes, protein truncations, or alternative splicing defects. However, it is often unclear how mutation of a gene ultimately leads to a clinical phenotype such as neurodegeneration. Dissecting the relevant molecular pathways is essential for our understanding, but by using classical methods it is laborious and time consuming. Using a variety of assays in HT-HCS, one will be able to obtain a complete profile of all upstream regulators (transcriptional and translation and posttranslational regulators and ncRNAs) as well as the downstream consequences (e.g., neurite outgrowth, synapse formation and/or function, protein folding) of the wild-type and mutant protein (Figure 3 ) by systematically testing all combinations of genes within a pathway. For example, DJ-1 is a gene involved in early onset parkinsonism (Bonifati et al., 2003) that acts as a sensor and protector for oxidative stress. In the past years, large numbers of studies discovered other genes that interact with DJ-1 by using a wide range of techniques. To test for the biological relevance of these reported interactions, one can perform an enhancer/suppressor screen by systematically testing the effect of the knockdown by shRNA of all these genes on the background of a cell line that is deficient in DJ-1 expression under oxidative stress conditions. This methodology will enhance our understanding of gene function with regard to the phenotypes they control or affect as well as the pathways in which they function and will allow us to focus on those genes that are most relevant for the disease pathogenesis.
In contrast, for multifactorial disease, GWAS have revealed large numbers of risk factors with mild effects that are often noncoding and have a biological effect that is not obvious. This will hopefully be partly resolved with the improved annotation of our genome by projects such as ENCODE and FANTOM (Birney et al., 2007; Carninci et al., 2005; Katayama et al., 2005) . However, by using a multiparametric cellular readout one has a much greater chance of detecting functional effects of risk factors that are more subtle than those found using simple one-dimensional whole-well readouts (Figure 3 ). Recent developments in ES and iPS cells have also opened up interesting new possibilities for HT-HCS in understanding multifactorial disorders as it is clear that simple single gene knockouts or overexpression studies will not do justice to the complexity of the diseases. Patient-derived iPS cells from nonfamilial cases have a more innate cellular background than typical exogenous expression systems; they thus may provide a more predictive cell-based screening strategy because these diseases are the result of tens to hundreds of risk factors that jointly and in different combinations lead to clinical phenotype. Yet while ES and iPS are a very promising model system, we have to be realistic in that the efficiency of the current protocols for differentiation into neurons, for example, are not yet at a useful level.
At the moment, a pragmatic approach to understanding the relation of risk factors to disease is to focus on two or three major factors at any one time and subsequently combine the resulting effects of each separate pathway into a new model. For example, one could quantify the biological effect of a limited number of risk factors (e.g., manipulate their expression level, or function in the cell) followed by a systematic enhancer/ suppressor screen using transient single-gene knockdown or overexpression. As an additional factor, one could use an environmental stress such as oxidative stress. As throughput is improving, testing all possible combinations of the perturbations will allow a genome-wide matrix approach to determine hierarchies, interactions, and epistatic effects between pathways. Such a method comes close to a systems biology approach that seeks to integrate a wide range of high-throughput biological studies to understand how biological systems function by studying the relationships and interactions between various parts of a biological system (e.g., metabolic pathways, organelles, cells, physiological systems, etc.) and by reducing the complexity of a network by identifying modules of functionally related elements.
To answer the second question of how HT-HCS can help to fulfill the promises of genetics for therapy development, we need to determine whether the identified genetic risk factors are appropriate targets for drug development. Typically, a drug target is a key molecule involved in a particular metabolic or signaling pathway that is specific to a disease condition or pathology. The target should be accessible by a chemical compound to modulate its function. As a result, the most common drug targets are G protein-coupled receptors (target of 50% of drugs), enzymes like protein kinases, ligand-gated and voltage-gated ion channels, and nuclear hormone receptors (Aherne et al., 2002) . In addition to the above, drugs should be designed in such a way as not to have undesirable side effects. Many of the identified genetic factors in neurodegenerative diseases have broad functions that are not limited to the brain. In fact, many of the genetic factors are ubiquitously expressed in the body, function in multiple molecular pathways, and therefore may not be an ideal target for drug development. The true value of identified factors might not be their use as a drug target, but that they act at the very start of the pathogenic process and point to crucial molecular pathways that are involved in disease. Targeting other key genes in these pathways, ones that are perhaps more suitable as a drug target, is therefore an important alternative strategy to develop therapeutics. As HC analysis can now be combined with HT, researchers can perform genomewide knockdown and overexpression studies to describe new gene networks and interactions in detail. In combination with data derived from other ''omics'' approaches, key genes in the disease pathways can be assessed for the ability to regulate 
Figure 3. Applications of HT-HC Screens
Mutations or risks factors can affect the function of protein at numerous different levels. Screening can be used to identify all pathways that control the transcription, translation, and degradation of the protein as well as determine the pathogenic mechanism of mutations or risk factors. Assays that are able to quantify the specific mechanism of the mutation (e.g., protein aggregation, disrupted alternative splicing) can also be used in drug screening. If the primary mechanism of the mutation or the protein is not accessible, the identification of the interacting pathways may yield a more suitable target.
pathogenesis as well as suitability as a drug target. Moreover, as one is able to monitor several process simultaneously, side effects of drugs can be detected with greater ease, reducing the number of compounds that are carried through for optimization and adsorption distribution, metabolism, elimination, and toxicity testing (ADMET) (Aherne et al., 2002; Eglen et al., 2008a ). Although we feel that HT-HCS holds great promise, by itself it will not be able to provide a complete understanding of all the dynamic complex interactions in a biological system. In order to obtain an accurate systems biology perspective, data sets from individual screens as well as from other ''omics'' approaches, such as genomics, transcriptomics, and proteomics, will need to be integrated as was recently discussed (Geschwind and Konopka, 2009) . To facilitate the integration of data sets, reliable and validated screen data need to be made publicly available with detailed descriptions about the screen in a similar fashion as has been implemented for publication of mRNA expression data. As yet there are no public repositories or regulations for making the data publically available, but as more and more screens are being performed the need for guidelines increases. Reporting data should include thorough information about the assay with respect to sensitivity, dynamic range, signal intensity, stability, and validation as well as full experimental particulars, data collection, and analysis methods as reviewed by Inglese et al. (2007b) and Stone et al. (2007) .
Conclusions
From the early days when only the effect of a compound on a single or simple mixture of proteins could be quantified, HT screening has evolved to a situation where one can now gather vast amounts of detailed information on practically any cellular process or molecular event, which will greatly expedite our understanding of complex biological systems. Combined with continuing advances in molecular tools, cellular models, livecell imaging, and data analysis, HT-HC cellular screening will be able to provide important answers on the function of genes and gene networks within the cellular matrix that are needed to improve our understanding of the pathogenesis of neurological diseases.
HT-HC cellular screens can be instrumental in unraveling the heritability of multifactorial disorders. Part of the ''missing heritability'' can be identified by searching for epistatic interactions between genes. Now that statistical methods to detect such interaction are being developed, HT-HC screening can provide the functional validation of these interactions. HT-HC cellular screens can thus form an important link between genetics and genomics and more detailed studies on a cell biological (single-molecule) level by providing functional validation of predicted effects for the wealth of HT data from GWAS studies and other genomic datasets. On the other hand, although automated imaging, cell culture, and the availability of genome-wide RNAi resources have made genome-wide high-resolution cellular screens possible, its success is highly dependent on the quality and resolution of the assays that are built. The basis for such assays must be provided by detailed cell and molecular biological studies, and the integration of all these approaches can finally provide a better translation of genetic findings into better targets for therapy development.
